Jun 14, 2022 | Business
Olympus Corporation (“Olympus” – Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) announces that from April 2022, the company has begun to exclusively source 100% of the electricity used at its major R&D and manufacturing sites in Japan from renewable sources.
As a result, CO2 emissions from Olympus Group facilities in Japan will be reduced by approximately 40,000 tons per year. The percentage of the Olympus Group’s total electricity use* in fiscal 2023 (ending March 2023) from renewable energy sources is expected to substantially increase from approximately 14% in the previous fiscal year to approximately 70%.
– Transition to Renewable Energy Usage across the Olympus Group (Facilities in Japan and Overseas)
FY2020 11.7%
FY2021 12.7%
FY2022 (estimate) 14% (approx.)
FY2023 (estimate) 70% (approx.)
*Excluding recently acquired companies, certain service offices, and certain sales offices.
Olympus has set a goal of achieving net zero CO2 emissions from its site operations by 2030, as part of its commitment to achieving environmentally responsible business growth and creating a sustainable society. This is a key goal in line with our ESG materiality targets focused on the theme of a “carbon neutral society and circular economy.”
The company has already introduced a wide range of initiatives to reduce CO2 emissions. This includes the use of 100% renewable energy at some manufacturing sites in Europe and the United States, the installation of solar power generation facilities at some manufacturing sites in Japan, and support of the recommendations made by the Task Force on Climate-related Financial Disclosures (TCFD)*.
To achieve its carbon neutral goal, Olympus will continue to optimize manufacturing processes and promote energy-saving measures, is committed to further accelerate the shift to renewable energy sources across the company, thereby contributing to the decarbonization of society on a global level.
About Olympus
Olympus is passionate about creating customer-driven solutions for the medical, life sciences, and industrial equipment industries. For more than 100 years, Olympus has focused on making people’s lives healthier, safer and more fulfilling by helping to detect, prevent, and treat disease; furthering scientific research; and ensuring public safety. Olympus is headquartered in Tokyo, Japan, with more than 30,000 employees worldwide in nearly 40 countries and regions. For more information, visit www.olympus-global.com and follow our global Twitter account: @Olympus_Corp (https://twitter.com/olympus_corp).
Olympus Contact
Communications
Contact Olympus: https://www.olympus-global.com/products/contact/
*News release “Olympus Targets Carbon Neutrality by 2030 – Adds Carbon Neutrality and Circular Economy to its ESG Materiality and Supports the Recommendations of the Task Force on Climate-Related Financial Disclosures”:
https://www.olympus-global.com/news/2021/contents/nr02125/nr02125_00001.pdf
Topic: Press release summary
Dec 3, 2021 | Business
Olympus Corporation (“Olympus” – Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) has been selected for inclusion in the 2021 Dow Jones Sustainability World Index (DJSI World) and the 2021 Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), among the world’s most recognized corporate sustainability indices. Olympus is admitted to the DJSI World for the first time this year and in the DJSI Asia Pacific for the third consecutive year.
The Dow Jones Sustainability Indices (DJSI) are corporate sustainability evaluation indices for environmental, social and governance (ESG) investment. Jointly developed by S&P Dow Jones Indices and RobecoSAM, the DJSI track the financial performance of leading companies in terms of ESG criteria. Companies with excellent corporate sustainability practices are assured and selected annually.
In 2021, 322 companies were selected as DJSI World members from approximately 3500 companies in 61 industry sectors that were evaluated worldwide, and 153 companies were selected as DJSI Asia Pacific members from approximately 600 companies assessed in the region. Olympus is one of only 10 out of 84 companies to have been selected as DJSI World in the Health Care Equipment & Supplies sector. Our scores on Corporate Governance, Innovation Management, Operational Eco-Efficiency, Occupational Health and Safety initiatives have improved this year and those efforts were highly rated.
In addition to DJSI World and DJSI Asia Pacific, Olympus was also named in the FTSE4Good Index Series and FTSE Blossom Japan Index.
Based on Our Purpose of “Making people’s lives healthier, safer and more fulfilling,” Olympus believes that the sustainability of a company will be recognized primarily by meeting the demands and expectations of society and fulfilling our responsibilities through dialogue with all stakeholders. Since announcing our material issues (materiality)*1 at the beginning of our Corporate Strategy in 2019, we have further strengthened our efforts to address ESG challenges. We will continue to contribute to a sustainable society by actively engaging in activities that incorporate ESG perspectives to fulfill our corporate social responsibilities on a global scale.
For more information on our ESG initiatives, please refer to the Integrated Report 2021*2 and the Sustainability Report 2021*3.
*1: The following five materiality items were identified; “Healthcare access and outcomes”, “Compliance, product quality and safety”, “Responsible supply chain”, “Diversity and inclusion”, and “Carbon neutral society and circular economy” (this item was added in May, 2021).
*2: https://www.olympus-global.com/ir/data/integratedreport/pdf/integrated_report_2021e_A4.pdf
*3: https://www.olympus-global.com/csr/download/pdf/Olympus_Sustainability_Report_2021e.pdf
About Olympus
Olympus is passionate about creating customer-driven solutions for the medical, life sciences, and industrial equipment industries. For more than 100 years, Olympus has focused on making people’s lives healthier, safer and more fulfilling by helping to detect, prevent, and treat disease; furthering scientific research; and ensuring public safety. Olympus is headquartered in Tokyo, Japan, with more than 30,000 employees worldwide in nearly 40 countries and regions. For more information, visit www.olympus-global.com and follow our global Twitter account: @Olympus_Corp.
Olympus Contact (Tokyo)
Yuka Horimoto
+81-90-2490-1071
yuka.horimoto@olympus.com
Sourc
Nov 12, 2021 | Business
Olympus Corporation (Tokyo: 7733), a global leader in medical technology, has announced the establishment of Olympus Innovation Ventures to invest in pioneering startups with innovative technologies that improve clinical outcomes, reduce healthcare costs and enhance the quality of life for patients.
Olympus Innovation Ventures, a fully-owned subsidiary of Olympus Corporation of the Americas, is a venture capital fund focused on startups poised to improve patient outcomes, radically advance the detection and treatment of disease, and transform the surgery suite. The new fund expands upon Olympus’ strategy to strengthen endoscopy and pioneer next-generation tools and procedures for minimally invasive surgery.
Olympus’ venture fund is stage-agnostic, prioritizing early- and growth-stage companies globally with solutions in therapeutic areas including gastroenterology, respiratory, and urology. Olympus has allocated $50 million for initial commitments and follow-on investments in portfolio companies. In addition to capital, Olympus will help its portfolio companies succeed by contributing its clinical and technical expertise, access to healthcare professionals and hospitals, and ability to launch and scale innovative solutions in the global market.
Olympus has been a leader in optical and medical innovation for over 100 years, introducing a mass-produced microscope to Japan in 1919 and the world’s first gastrocamera for practical use in 1950. Olympus’ tools have aided the minimally invasive surgery revolution and have evolved to detect and treat disease. Yasuo Takeuchi, CEO of Olympus Corporation, says “Our investment underscores our commitment to make people’s lives safer, healthier, and more fulfilling. Our goal is for this fund to continue our history of innovation and support our long-term growth and transformation.”
Touchdown Ventures, a firm specializing in corporate venture capital, will help manage the Olympus Innovation Ventures fund. Touchdown will work closely with senior executives of Olympus in all aspects of operating the fund.
“We are excited about what Olympus can bring to entrepreneurs through the company’s technical strengths, industry relationships, vast distribution, and deep subject matter expertise,” noted Scott Lenet, co-founder and President of Touchdown Ventures. “The entire Olympus Innovation Ventures team is working to be the partner of choice for innovators and create a competitive advantage for their startups.”
Nacho Abia, Chief Operating Officer of Olympus Corporation, said “This effort is another way Olympus is demonstrating its commitment to excellence and creating tangible value for providers and patients. We believe we will play a meaningful role in the advancement of minimally invasive care and new ways to detect, monitor and treat conditions and diseases.”
For more information, please visit http://olympusamerica.com/venture-capital. Olympus Innovation Ventures can be contacted at ventures@olympus.com.
For the contact:
Olympus Corporation of the Americas
Christos Monovoukas
Vice President, Global Business Development
Christos.Monovoukas@Olympus.com
Touchdown Ventures
Deborah Zajac
Director, Investments
deborah@touchdownvc.com
About Olympus
Olympus is passionate about creating customer-driven solutions for the medical, life sciences, and industrial equipment industries. For more than 100 years, Olympus has focused on making people’s lives healthier, safer and more fulfilling by helping to detect, prevent, and treat disease; furthering scientific research; and ensuring public safety. As a leading medical technology company, our Medical business uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients and their safety. Olympus’ Medical portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, system integration solutions, medical services, and a wide range of endotherapy instruments for endoscopic and therapeutic applications. For more information, visit www.olympus-global.com.
About Touchdown Ventures
Touchdown Ventures partners with corporations to manage their venture capital programs. Touchdown works closely with each corporation to achieve the financial and strategic benefits from venture capital investments. The firm is a Registered Investment Adviser and maintains offices in Los Angeles, Philadelphia, and San Francisco. More information on Touchdown can be found at www.touchdownvc.com
Olympus Contact (Tokyo)
Yuka Horimoto
+81-90-2490-1071
yuka.horimoto@olympus.com
Olympus Contact (USA)
Susan Scerbo
+1-610-909-9153
sue.scerbo@olympus.com
Touchdown Ventures Contact
Deborah Zajac
Director, Investments
+1-917-558-4403
deborah@touchdownvc.com
Topic: Press release summary
Apr 8, 2021 | Business
Olympus Corporation (“Olympus” – Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) announced today the opening of a new facility in Westborough, MA, to serve as the global headquarters for its Therapeutic Solutions Division (TSD) and its medical business in the United States.
Olympus has identified TSD as a strategic focus for growth and shifted its global head of TSD from Tokyo to the U.S. to have better access to a key medical industry cluster and generate growth through stronger business opportunities. Since the Transform Olympus initiatives were unveiled in 2019, many U.S.-based executives have been leading TSD growth; Olympus has dramatically expanded the business with acquisitions, as well as through organic growth.
The new 150,000-square-foot facility in Westborough will accommodate both the U.S. TSD employees and those formerly reporting to Image Stream Medical (ISM) facility located in Littleton, MA, with the exception of the manufacturing employees who will remain in Littleton. The facility will serve as one of several R&D hubs for Olympus, while enabling coordinated and agile management processes to support a global medical technology enterprise. At Olympus Westborough, the Olympus Continuum Training and Education Center will offer hands-on learning opportunities led by top medical experts using advanced medical equipment in a wetlab setting, both in person and virtually via the MedPresence telecollaboration platform. For interactions with customers and prospects, the Olympus OR Innovation Center showroom, also outfitted with the MedPresence platform, will provide an immersive environment for in-person or virtual integrated OR demonstrations.
The new Westborough facility will also provide enhanced opportunities for Olympus to build relationships with potential future employees. Olympus will facilitate relationships with potential job candidates, as well as continued partnerships with universities, colleges, and technical schools in the greater Boston area to bring world-class skills and capabilities to the company.
Nacho Abia, Chief Operating Officer of Olympus Corporation, said, “The U.S. market continues to be the largest in the world because of growing demand for minimally invasive treatment and surgery and the need for remote collaboration under COVID-19, so it’s natural that we decided to combine all functions in Massachusetts in one place to facilitate agility and collaboration. This agile and globally-connected way of business will enhance our overall business competitiveness.”
About Olympus’ Medical business
As a leading medical technology company, our Medical business uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients and their safety. Olympus’ Medical portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, system integration solutions, medical services, and a wide range of endotherapy instruments for endoscopic and therapeutic applications. For more information, visit www.olympus-global.com.
For questions or additional information, please contact:
United States
Jennifer Bannan
+1 412-403-8742
[email protected]
Europe, Middle East and Africa
Matthias Gengenbach
+49 15142369420
[email protected]
Japan and APAC
Yuka Horimoto
+81-90-2490-1071
[email protected]
Topic: Press release summary
